Other substances

rAd5-S

An experimental adenoviral vaccine with the SARS-CoV-2 Spike protein immunogen.

Phase of research

Potential treatment - clinical evidence

How it helps

Vaccine

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
1
 AI-suggested references
0
 Clinical trials

General information

rAd5-S is an experimental vaccine in phase I/II clinical trials (NCT04436471 and NCT04437875). It is based on adenoviral vector carrying the gene for the SARS-CoV-2 spike protein. Preliminary results suggest its safety and immunogenicity in healthy individuals (Logunov et al., 2020).

 

Supporting references

Link Tested on Impact factor Notes Publication date
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia
Non-randomized non-controlled open trial Viral vector Phase II clinical trial Phase I clinical trial 		Healthy adults 60.39

The experimental vaccine produces strong humoral and cellular immune responses in healthy adults without serious side effects. Sample size: 9 (phase I) + 20 (phase II) (with preceding rAd26-S administration). Dosage: IM; in the phase II, rAD5-S administration was preceded by rAd26-S (21 days).


 Sep/04/2020

AI-suggested references

Link Publication date
Potency, toxicity and protection evaluation of PastoCoAd candidate vaccines: Novel preclinical mix and match rAd5 S, rAd5 RBD-N and SOBERANA dimeric-RBD protein
Apr/04/2022
Export (.csv)